Enhancing Clinical Trial Insights with Advanced Tools for Treatment Effect Heterogeneity

Clinical trials evaluate efficacy and safety in defined populations, yet treatment responses often vary due to biological, clinical, and demographic factors. Understanding this heterogeneity is critical for characterizing therapeutic effects across subgroups and guiding regulatory decision-making (e.g., FDA guidance, May 2023). We present a flexible analytical framework that integrates traditional and modern machine learning (Random Forests, Elastic Net, Neural Networks) with Bayesian extensions and causal inference methods—including Virtual Twins (VT) for individualized treatment effects, Targeted Maximum Likelihood Estimation (TMLE) and Debiased Machine Learning (DBL) for robust causal estimation, and conformal prediction for principled uncertainty quantification. Applied to synthetic ulcerative colitis trial data, the framework (i) identifies influential covariates, distinguishing prognostic from predictive effects; (ii) uncovers clinically meaningful subgroups; and (iii) produces uncertainty – calibrated estimates under rigorous statistical inference. By addressing model misspecification, overfitting, and interpretability, these synergistic approaches enhance the robustness of inference and support evidence-based clinical development and regulatory assessments.

Key Words: Bayesian, machine learning, Virtual Twins, causal inference, conformal prediction, efficacy, ulcerative colitis, clinical trials